Clinical Trial

A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight

Completed Phase 1
View on ClinicalTrials.gov →
Summary
Novo Nordisk is developing a new study medicine NNC0519-0130 to improve the treatment options for people living with type 2 diabetes and excess body weight. In this study, the concentration of NNC0519-0130 in the blood will be measured and its safety will be evaluated. The participants will either get NNC0519-0130 or placebo (a "dummy" substance), which treatment the participants get is decided by chance. This study will test up to 7 different doses of NNC0519-0130 and will last for about 28 weeks.
Protocol Amendment History 3 changes
critical Trial completed 2026-04-01
notable Primary completion moved earlier: 2026-04-07 -> 2026-01-28 2026-04-01
minor Completion moved earlier: 2026-04-07 -> 2026-01-28 2026-04-01
Trial Details
NCT Number NCT07004322
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 2, Obesity
Enrollment 20 participants
Start Date 2025-05-26
Primary Completion 2026-01-28 (estimated)
Study Completion 2026-01-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-31